The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

CIDP Companies across the globe are diligently working toward developing novel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) treatment therapies with a considerable amount of success ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, Mechanism of Action, Route of Administration by DelveInsight ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy <li /> Two phase 3 studies ar ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of autologous anti-CD19 CAR T-cells.

US FDA grants fast track designation to Sanofi’s SAR446597 to treat geographic atrophy due to age-related macular degeneration: Paris Thursday, July 17, 2025, 10:00 Hrs [IST] Th ...

The National Organization for Rare Disorders (NORD®) is honoring a distinguished group of industry leaders and individuals for their contributions to help improve the lives of more than 30 million ...

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration Designation earned for a one-time intravitreal gene therapy designed to inhibit ...

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

Argenx SE (NASDAQ:ARGX) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 16, Bank of America Securities analyst Tazeen Ahmad maintained a bullish stance on Argenx SE (NASDAQ:ARGX), ...

Explore guideline-based treatments for Restless Legs Syndrome, from iron therapy to medications and alternative therapies that improve sleep.

"Sanofi’s riliprubart gains ODD status from Japan’s MHLW for CIDP" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.